News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
389,517 Results
Type
Article (18633)
Company Profile (125)
Press Release (370759)
Section
Business (120893)
Career Advice (707)
Deals (23567)
Drug Delivery (74)
Drug Development (56186)
Employer Resources (67)
FDA (9761)
Job Trends (8547)
News (214051)
Policy (19840)
Tag
Academia (896)
Alliances (29965)
Alzheimer's disease (736)
Approvals (9736)
Artificial intelligence (89)
Bankruptcy (218)
Best Places to Work (6545)
Biotechnology (57)
Breast cancer (69)
Cancer (714)
Cardiovascular disease (65)
Career advice (619)
Cell therapy (143)
Clinical research (45964)
Collaboration (237)
Compensation (84)
COVID-19 (1181)
C-suite (66)
Data (833)
Diabetes (98)
Diagnostics (2992)
Drug pricing (69)
Earnings (50265)
Employer resources (58)
Events (55896)
Executive appointments (210)
FDA (10122)
Funding (191)
Gene therapy (116)
GLP-1 (363)
Government (2091)
Healthcare (8243)
Infectious disease (1222)
Inflammatory bowel disease (71)
Interviews (97)
IPO (10747)
Job creations (2313)
Job search strategy (552)
Layoffs (190)
Legal (4371)
Lung cancer (105)
Manufacturing (128)
Medical device (5365)
Medtech (5368)
Mergers & acquisitions (12921)
Metabolic disorders (265)
Neuroscience (912)
NextGen Class of 2024 (2670)
Non-profit (1200)
Northern California (935)
Obesity (151)
Opinion (141)
Patents (84)
People (34572)
Pharmaceutical (67)
Phase I (13813)
Phase II (20164)
Phase III (15719)
Pipeline (376)
Postmarket research (1640)
Preclinical (5405)
Radiopharmaceuticals (164)
Rare diseases (144)
Real estate (3172)
Regulatory (14168)
Research institute (942)
Resumes & cover letters (89)
Southern California (843)
Startups (1984)
United States (8447)
Vaccines (196)
Weight loss (115)
Date
Today (67)
Last 7 days (428)
Last 30 days (2373)
Last 365 days (23539)
2024 (21585)
2023 (26076)
2022 (33043)
2021 (34276)
2020 (32187)
2019 (23604)
2018 (17974)
2017 (20129)
2016 (18371)
2015 (22004)
2014 (16825)
2013 (13797)
2012 (14600)
2011 (15378)
2010 (14158)
Location
Africa (418)
Arizona (68)
Asia (27880)
Australia (5629)
California (2078)
Canada (935)
China (180)
Colorado (93)
Connecticut (105)
Europe (53441)
Florida (298)
Illinois (179)
Indiana (124)
Japan (59)
Kansas (59)
Maryland (304)
Massachusetts (1676)
Minnesota (108)
New Jersey (731)
New York (647)
North Carolina (450)
Northern California (935)
Ohio (64)
Pennsylvania (574)
South America (662)
Southern California (843)
Texas (311)
Washington State (275)
389,517 Results for "neuren pharmaceuticals limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.
May 27, 2024
·
8 min read
Drug Development
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS).
December 18, 2023
·
7 min read
Deals
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591.
July 13, 2023
·
11 min read
Deals
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
April 11, 2024
·
3 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
BioCapital
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.
April 17, 2024
·
5 min read
Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley
June 3, 2024
·
4 min read
Press Releases
Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
November 6, 2024
·
3 min read
Piramal Pharma Limited Announces Results for Q4 and FY2024
Piramal Pharma Limited, a leading global pharmaceuticals company, announced its standalone and consolidated results for the Fourth Quarter and Full Year ended 31st March 2024.
May 10, 2024
·
8 min read
Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split
Qilian International Holding Group Limited, a China-based pharmaceutical and chemical products manufacturer, announced that an 1 for 5 reverse split of its authorized share capital, was approved by the Company’s board of directors on May 29, 2023 and will become effective on June 21, 2024.
June 18, 2024
·
4 min read
1 of 38,952
Next
